Arthrofibrosis of Knee Clinical Trial
Official title:
Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty
The purpose of this study is to determine the effect of Losartan, an Angiotensin II Receptor Blocker (ARB), on the formation development of arthrofibrosis in patients who have had a primary total knee arthroplasty. This study aims to assess the post-operative range of motion and the incidence of MUA within three months following the index arthroplasty in the treatment arm (losartan) and the control arm.
n/a